Bayer's drug business has been on a roll, thanks to some serious growth in its 5 newest products, including the clot-fighter Xarelto and the PAH med Adempas.
In March, Bayer CEO Marijn Dekkers boldly predicted that the company's 5 new drugs--including the blood thinner Xarelto and the macular degeneration treatment Eylea--would help his company achieve 8% annual sales growth through 2016. Judging from the company's second quarter results, Bayer is well on its way to making good on that goal.
Regeneron is turning to gene therapy research to look for a successor to its blockbuster wet AMD drug Eylea.
The CEO of the German drugmaker is pinning some numbers on the medium term; the Big 5 will help Bayer aim for an average of 8% annual growth in its pharma unit through 2016, Marijn Dekkers said Wednesday.
Bayer knows what a good launch can do; with blood thinner Xarelto and eye drug Eylea, it's had a couple of the recent best. Thanks to that pair of hot-selling meds, the German pharma raised the sales forecast for its new products by €2 billion late last week--and it's raising its marketing budget along with it.
Blood thinner Xarelto and eye med Eylea pack a pretty good one-two-punch. Those new drugs helped Bayer's pharma sales climb 9.4% in 2013, and they're not stopping: They'll ultimately lead a group of 5 recently launched products to sales of €7.5 billion ($10.3 billion) or more, CEO Marijn Dekkers said Friday.
Regeneron's hot-selling eye drug Eylea has done a lot in its short life, including post $1.4 billion in 2013 U.S. sales--and make the company's veteran CEO, Len Schleifer, into a billionaire.
After 25 years at the helm of one of biotech's best-case scenarios, Regeneron CEO Leonard Schleifer has crossed the $1 billion threshold, according to Forbes, thanks largely to the company's blockbuster eye drug. And, with a stable of promising late-stage treatments waiting in the wings, the Tarrytown, NY, executive's most profitable work may still be ahead of him.
Yesterday, Regeneron CEO Len Schleifer announced that r ather than the $377 million expected by analysts, Regeneron will report about $400 million in U.S. sales for macular degeneration treatment Eylea in the fourth quarter, Bloomberg reports.
Partners Regeneron and Bayer are hoping to piggy-back on their success with the wet age-related macular degeneration blockbuster Eylea, reuniting to develop a new drug that could become part of a combination therapy for the disease.